Press Release
17 September 2021

Sectoral Asset Management And Andera Partners Lead The $80 Million Series B Financing Round Of Amolyt Pharma

The Goodwin Technology team advised Sectoral Asset Management and Andera Partners in leading the $80 million Series B financing round of Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases.

The financing also included the participation from ATEM Capital and all investors from the company’s July 2019 Series A financing, including LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.

Funds will be used to continue the clinical development of AZP-3601 for hypoparathyroidism while progressing AZP-3813 through IND-enabling activities in acromegaly and further expanding early-stage pipeline.

The Goodwin team was led by Thomas Dupont-Sentilles and included Louis Taslé d’Héliand on corporate aspects.

For more information, read the press release.